Adamax vs Trofinetide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Semax derivative
Adamax is sold widely as an enhanced Semax derivative, and it is one of the clearest examples of a compound where availability has run far ahead of information. Vendors list it, forums discuss it, and there is essentially no peer-reviewed literature under this name. This page tells you what is actually known, what is inferred from its parent compound, and where the honest gaps are, because pretending otherwise would not help you.
Also: Daybue, Daybue Stix
Trofinetide is a synthetic version of a tiny three-amino-acid fragment (glycine-proline-glutamate) that the body clips off IGF-1. It is the first drug ever approved for Rett syndrome: the FDA approved it as Daybue in March 2023 for patients 2 years and older, Health Canada followed in October 2024, and the EU authorised it as Daybu in August 2026 after first refusing it. It is a real, approved medicine with a real but modest effect, and the trade-off is blunt: most patients get diarrhea, and a meaningful share stop because of it.
Key Comparison Insights
- Trofinetide is FDA approved, while Adamax remains in research stages.
- Both peptides belong to the Cognitive category, suggesting similar primary applications.
- Trofinetide has stronger research evidence (FDA Approved) compared to Adamax (Preclinical).
Detailed Comparison
| Attribute | Adamax | Trofinetide |
|---|---|---|
| Category | Cognitive | Cognitive |
| FDA Status | Not FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | What is claimed is that Adamax is a structurally modified Semax analog, with modifications intended to improve stability and blood-brain barrier penetration relative to Semax itself. Semax is a synthetic fragment of ACTH (4-10) developed in Russia, and its best-supported mechanism is upregulation of BDNF and NGF in the hippocampus and cortex, alongside modulation of the monoamine systems and some effect on the melanocortin pathway. If Adamax is what it is sold as, its mechanism should be broadly that of Semax with altered pharmacokinetics. That is a reasonable inference and it is not the same thing as a demonstrated mechanism. No published pharmacology characterises Adamax specifically. | Rett syndrome is usually caused by loss-of-function mutations in the MECP2 gene, which disrupts how neurons mature and connect. Trofinetide is an analog of GPE, the N-terminal tripeptide of IGF-1, built to survive longer in the body than the natural fragment. In Mecp2-deficient mice, GPE partially reversed Rett-like symptoms, and the working theory is that trofinetide supports synaptic function and dampens neuroinflammation. The honest part: the FDA label states that the mechanism by which trofinetide works in Rett syndrome is unknown. It is taken by mouth in large gram-level doses, has an elimination half-life of about 1.5 hours, and is cleared mainly by the kidneys, which is why it is not recommended in moderate or severe kidney impairment. |
| Common Dosing | 100-300 mcg daily Once daily, morning | 5-12 g twice daily, set by body weight (labeled dose) Twice daily, morning and evening |
| Administration | Intranasal is the most commonly reported route, following Semax practice. Subcutaneous is also reported. | Oral solution (200 mg/mL) by mouth or via gastrostomy tube; also available as a powder (Daybue Stix) mixed into liquid |
| Typical Duration | Community protocols typically report 2-4 week blocks rather than continuous use | Ongoing for the approved indication; dose is interrupted, reduced, or stopped for severe diarrhea, dehydration, or significant weight loss |
| Best Time to Take | Morning | Morning and evening, as prescribed |
Possible Side Effects May vary by individual |
|
|
| Research Summary | There is no peer-reviewed clinical or preclinical literature on Adamax under that name that stands up to a search. What exists is a substantial Russian-language research base on Semax, its parent, which includes clinical use in Russia for stroke recovery, cognitive impairment and optic nerve conditions, and which supports the BDNF and NGF mechanism. Extending that evidence to Adamax requires assuming the analog behaves like the parent, and no published work confirms that assumption. Everything circulating about Adamax's potency relative to Semax is vendor claim and user report, not measurement. The honest position is that this is an uncharacterized research compound whose parent has real but largely non-Western evidence behind it. If you want the compound with actual literature, that compound is Semax. | Approval rests on one pivotal trial, LAVENDER (Neul and colleagues, Nature Medicine 2023): 187 girls and young women aged 5 to 20 with Rett syndrome, randomized to trofinetide or placebo for 12 weeks. Both co-primary endpoints were hit. The caregiver-rated Rett Syndrome Behaviour Questionnaire improved by 4.9 points versus 1.7 on placebo, and the clinician-rated CGI-I score was 3.5 versus 3.8, with effect sizes in the small-to-moderate range (Cohen's d 0.37 and 0.47). A communication measure also favored the drug. The price was tolerability: diarrhea hit about 81% on trofinetide versus 19% on placebo, vomiting 27% versus 10%, and 17% dropped out for side effects (mostly diarrhea). The label adds that 12% lost more than 7% of body weight. Open-label extensions (LILAC and the 32-month LILAC-2, published in Med in 2024) reported continued improvement, but without a placebo arm those data cannot prove the drug caused it. In December 2025 the FDA approved Daybue Stix, a powder version, based on a bioequivalence study. In Europe, the EMA's committee first refused the application in February 2026, then recommended approval on re-examination in June 2026 for patients 5 and older, noting the improvements were small but relevant for a serious disease and that the trial showed no effect on seizures. Bottom line: a genuine first treatment for a disease that had none, with modest benefit and a heavy GI cost. |
Frequently Asked Questions: Adamax vs Trofinetide
What is the difference between Adamax and Trofinetide?
Adamax is a cognitive peptide that adamax is sold widely as an enhanced semax derivative, and it is one of the clearest examples of a compound where availability has run far ahead of information. vendors list it, forums discuss it, and there is essentially no peer-reviewed literature under this name. this page tells you what is actually known, what is inferred from its parent compound, and where the honest gaps are, because pretending otherwise would not help you. Trofinetide is a cognitive peptide that trofinetide is a synthetic version of a tiny three-amino-acid fragment (glycine-proline-glutamate) that the body clips off igf-1. it is the first drug ever approved for rett syndrome: the fda approved it as daybue in march 2023 for patients 2 years and older, health canada followed in october 2024, and the eu authorised it as daybu in august 2026 after first refusing it. it is a real, approved medicine with a real but modest effect, and the trade-off is blunt: most patients get diarrhea, and a meaningful share stop because of it. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Adamax or Trofinetide?
Neither is universally "better" - the choice depends on your specific goals. Adamax is typically used for cognitive purposes, while Trofinetide is used for cognitive. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Adamax and Trofinetide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Adamax and Trofinetide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.